Pharmacists in Castle Pines, CO Accepting Medicare

7 Pharmacists found. Showing 1 - 7

Mr. Michael Hunter, R.PH. Pharmacist - Pharmacist Clinician (PhC)/ Clinical Pharmacy Specialist Medicare: Not Enrolled in Medicare Practice Location: 8664 Fawnwood Dr, Castle Pines, CO 80108 Phone: 303-708-1800

Mr. Carson Mart Strickland, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7284 Lagae Rd, Castle Pines, CO 80108 Phone: 303-688-9762

Ms. Anna Maria Opala, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7066 Keech Way, Castle Pines, CO 80108 Phone: 303-218-8305

Michael Hankinson, PHARMD. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7284 Lagae Rd, Castle Pines, CO 80108 Phone: 303-688-9721

Magda Suyen Solari, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7370 Lagae Rd, Castle Pines, CO 80108 Phone: 720-214-2283

Dr. Folami S Osikoya, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7370 Lagae Rd, Castle Pines, CO 80108 Phone: 720-214-2283    Fax: 720-214-2289

Julia M Griffin, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7370 Lagae Rd, Castle Pines, CO 80108 Phone: 720-214-2283    Fax: 720-214-2289

News Archive

Medworxx announces addition of York Central Hospital

Medworxx Inc., a leader in clinical patient flow, compliance and education solutions, today announces the addition of York Central Hospital in Richmond Hill, ON, to the Medworxx Patient Flow community, licensing 370 beds at the hospital. York Central is located in one of Canada's fastest growing communities, and now joins the fold of Medworxx Patient Flow clients representing 38% of acute-care beds in Ontario, and 30% nationwide.

Coastal Genomics automates DNA purification process using 3D printing – accelerating cancer research, prenatal screening and numerous other fields by partnering with Sculpteo

Coastal Genomics, experts in life sciences automation, selected Sculpteo, a leader in online 3D printing and digital manufacturing, to develop unique components for an automated DNA purification process.

DoD recommends funding for Synta's STA-9584 for prostate cancer study

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Department of Defense (DoD) has recommended STA-9584, a novel vascular disrupting agent (VDA) currently in pre-clinical development at Synta, be funded for study in advanced prostate cancer.

MorphoSys announces updated clinical data on its proprietary drug candidate MOR208

MorphoSys AG today announced updated clinical data on its proprietary drug candidate MOR208. MOR208 is a potent anti-CD19 antibody with a proprietary modification to the Fc portion that is being developed to treat B-cell malignancies.

Clinical trial data for Perforomist Inhalation solution

Data presented at the International Conference of the American Thoracic Society (ATS) demonstrate that Perforomist (formoterol fumarate) Inhalation Solution, delivered by nebulization, is an effective and well-tolerated new treatment option for patients suffering from emphysema or chronic bronchitis, otherwise known as Chronic Obstructive Pulmonary Disease (COPD).

Read more Medical News

› Verified 4 days ago